Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.40 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6176466 | 0.90 | MAPT (0.47) | MAPTHSD11B1UTS2RPLA2G7BCL2L1 | |
| SCHEMBL6174293 | 0.88 | MAPT (0.62) | MAPTHSD11B1PLA2G7BCL2L1MCL1 | |
| SCHEMBL6176415 | 0.86 | MAPT (0.48) | MAPTHSD11B1UTS2RPLA2G7BCL2L1 | |
| SCHEMBL6175070 | 0.84 | UTS2R (0.46) | MAPTHSD11B1UTS2RLMNAHTT | |
| SCHEMBL6543128 | 0.81 | UTS2R (0.47) | MAPTUTS2RLMNAALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL6176770 | 0.79 | MAPT (0.59) | MAPTHSD11B1PLA2G7BCL2L1MCL1 | |
| SCHEMBL6176698 | 0.79 | MAPT (0.57) | MAPTHSD11B1UTS2RPLA2G7CACNA1B | |
| SCHEMBL6542898 | 0.79 | UTS2R (0.51) | MAPTUTS2RLMNAALDH1A1MEN1 | |
| SCHEMBL6178137 | 0.78 | UTS2R (0.49) | MAPTHSD11B1UTS2RPLA2G7GPR119 | |
| SCHEMBL6709360 | 0.77 | UTS2R (0.51) | MAPTHSD11B1UTS2RPLA2G7BCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399137-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-12-14 | — | — | EP | claimed |
| US-6849635-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-01 | — | — | US | claimed |
| US-20040152893-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | claimed |
| EP-1399137-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-03-24 | — | — | EP | claimed |
| WO-2002089785-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | claimed |
| EP-1399137-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-12-14 | — | — | EP | disclosed |
| US-6921765-B2 | 1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors | APREA AB (SE) | 2005-07-26 | — | — | US | disclosed |
| US-20050090540-A1 | 1-Azabicyclo [2,2,2] octan-3-one derivatives | APREA AB (SE) | 2005-04-28 | — | — | US | disclosed |
| US-6849635-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040152893-A1 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
| EP-1399137-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20030166674-A1 | 1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors | APREA THERAPEUTICS AB (SE) | 2003-09-04 | — | — | US | disclosed |
| WO-2002089785-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090540-A1 | 1-Azabicyclo [2,2,2] octan-3-one derivatives | TP53, ACIN1, BCLAF1 | MAPT 4055/4885HSD11B1 3210/4885UTS2R 4094/4885 |
| US-20030166674-A1 | 1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors | TP53, BBC3, ERCC2 | MAPT 3755/4885HSD11B1 3774/4885UTS2R 4022/4885 |
| US-20040152893-A1 | Sulfonamides | UTS2R, PRSS2, STS | MAPT 2260/4885HSD11B1 3366/4885UTS2R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.